0RQO Stock Chart & Stats
kr226.20
-kr0.20(-0.09%)
At close: 4:00 PM EDT
kr226.20
-kr0.20(-0.09%)
Day’s Range― - ―
52-Week Rangekr167.55 - kr321.50
Previous CloseN/A
Volume1.53K
Average Volume (3M)17.55K
Market Cap
kr15.02B
Enterprise Valuekr13.69K
Total Cash (Recent Filing)kr434.31M
Total Debt (Recent Filing)kr10.13M
Price to Earnings (P/E)70.4
Beta0.90
Next Earnings
Oct 22, 2026EPS Estimate
1.29Next Dividend Ex-DateN/A
Dividend Yield0.68%
Share Statistics
EPS (TTM)3.24
Shares Outstanding65,859,190
10 Day Avg. Volume16,478
30 Day Avg. Volume17,552
Financial Highlights & Ratios
PEG Ratio14.80
Price to Book (P/B)14.28
Price to Sales (P/S)10.54
P/FCF Ratio57.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.89
Revenue Forecast (FY)kr1.49B
Bulls Say, Bears Say
Bulls Say
High Revenue GrowthManagement’s reiterated 33–36% constant-currency growth outlook, supported by 31% first-half growth, indicates strong demand and expanding adoption. Sustained top-line momentum can reinforce market position, support operating leverage, and provide capacity to fund continued geographic and indication expansion.
Scalable ProfitabilityVery high gross margins and a 29% adjusted operating margin demonstrate attractive unit economics and meaningful scalability in the product model. These economics can support reinvestment in commercial capabilities and clinical evidence while preserving strong profitability as sales expand.
Low Leverage And Cash GenerationMinimal leverage gives BONESUPPORT substantial financial flexibility and reduces the burden of interest or refinancing risk. Strong recent free cash flow, which roughly matches net income, improves self-funded growth capacity and supports strategic investment or shareholder returns.
Bears Say
Growth DecelerationAlthough growth remains solid, the slowdown from earlier hyper-growth levels raises the risk that expansion is becoming harder to sustain. Slower revenue growth could reduce operating leverage, moderate earnings compounding, and increase dependence on successful new indications or geographic expansion.
Historically Volatile Cash FlowThe recent cash-flow improvement is encouraging, but prior periods of materially negative operating and free cash flow show that conversion has not been consistently proven across cycles. A recurrence would reduce internally funded investment capacity and make results less predictable.
Regulatory And Reimbursement UncertaintyFuture growth opportunities depend partly on regulatory and reimbursement outcomes that remain unresolved. Delays or unfavorable decisions could postpone product adoption, limit the addressable market, and require continued commercial investment without the expected incremental revenue contribution.
BONESUPPORT HOLDING AB News
0RQO FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest share price was kr167.55 and its highest was kr321.50 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is kr15.02B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Oct 22, 2026 which is in 45 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Jul 16, 2026. The company reported kr1.23 earnings per share for the quarter, beating the consensus estimate of kr1.13 by kr0.1.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB pays a Notavailable dividend of kr0.285 which represents an annual dividend yield of 0.68%. See more information on BONESUPPORT HOLDING AB dividends here
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 1.29.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of kr1.23 in its last earnings report, beating expectations of kr1.13. Following the earnings report the stock price went down -9.687%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in GB:0RQO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationally, including in Europe and North America. Among its key offerings are CERAMENT Bone Void Filler, a synthetic, injectable, moldable, and drillable solution comprising hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. Additionally, the company provides CERAMENT G, an injectable ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Bonesupport is also advancing preclinical product candidates focused on promoting bone regrowth. These future solutions are being developed for applications such as trauma, revision arthroplasty, chronic osteomyelitis, oncology, and bone and foot infections related to diabetes. Founded in 1999, the company maintains its headquarters in Lund, Sweden.
0RQO Company Deck
0RQO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: strong revenue growth (30% FX-adjusted), high adjusted margins (29%), solid cash generation and pronounced U.S. launch momentum for CERAMENT G. Material positives include regulatory progress, proposed CMS reimbursement improvements, and healthy EUROW performance. Headwinds include a small set of U.S. accounts temporarily restricting usage (modestly dampening growth), higher commercial and incentive costs, minor gross margin impacts from write-downs and tariffs, and uncertainty around the timing of regulatory approvals and study publications. On balance the company's growth trajectory and scalable profitability outweigh the transitory challenges discussed.View all GB:0RQO earnings summaries